These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 12076750

  • 1. Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir.
    Hossain MM, Coull JJ, Drusano GL, Margolis DM.
    Antiviral Res; 2002 Jul; 55(1):41-52. PubMed ID: 12076750
    [Abstract] [Full Text] [Related]

  • 2. Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine.
    Stone C, Ait-Khaled M, Craig C, Griffin P, Tisdale M.
    Antimicrob Agents Chemother; 2004 Apr; 48(4):1413-5. PubMed ID: 15047556
    [Abstract] [Full Text] [Related]

  • 3. Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine.
    Ray AS, Myrick F, Vela JE, Olson LY, Eisenberg EJ, Borroto-Esodo K, Miller MD, Fridland A.
    Antivir Ther; 2005 Apr; 10(3):451-7. PubMed ID: 15918336
    [Abstract] [Full Text] [Related]

  • 4. The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation.
    Svarovskaia ES, Feng JY, Margot NA, Myrick F, Goodman D, Ly JK, White KL, Kutty N, Wang R, Borroto-Esoda K, Miller MD.
    J Acquir Immune Defic Syndr; 2008 Aug 01; 48(4):428-36. PubMed ID: 18614922
    [Abstract] [Full Text] [Related]

  • 5. In vitro combination studies of tenofovir and other nucleoside analogues with ribavirin against HIV-1.
    Margot NA, Miller MD.
    Antivir Ther; 2005 Aug 01; 10(2):343-8. PubMed ID: 15865229
    [Abstract] [Full Text] [Related]

  • 6. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.
    Perez-Olmeda M, Garcia-Perez J, Mateos E, Spijkers S, Ayerbe MC, Carcas A, Alcami J.
    J Med Virol; 2009 Feb 01; 81(2):211-6. PubMed ID: 19107982
    [Abstract] [Full Text] [Related]

  • 7. Targeting of the purine biosynthesis host cell pathway enhances the activity of tenofovir against sensitive and drug-resistant HIV-1.
    Heredia A, Davis CE, Reitz MS, Le NM, Wainberg MA, Foulke JS, Wang LX, Redfield RR.
    J Infect Dis; 2013 Dec 15; 208(12):2085-94. PubMed ID: 23922365
    [Abstract] [Full Text] [Related]

  • 8. HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).
    Geleziunas R, Gallagher K, Zhang H, Bacheler L, Garber S, Wu JT, Shi G, Otto MJ, Schinazi RF, Erickson-Viitanen S.
    Antivir Chem Chemother; 2003 Jan 15; 14(1):49-59. PubMed ID: 12790516
    [Abstract] [Full Text] [Related]

  • 9. Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2-(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates.
    Palmer S, Shafer RW, Merigan TC.
    Antimicrob Agents Chemother; 1999 Aug 15; 43(8):2046-50. PubMed ID: 10428934
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.
    Winston A, Mandalia S, Pillay D, Gazzard B, Pozniak A.
    AIDS; 2002 Oct 18; 16(15):2087-9. PubMed ID: 12370512
    [Abstract] [Full Text] [Related]

  • 20. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors.
    Birkus G, Hitchcock MJ, Cihlar T.
    Antimicrob Agents Chemother; 2002 Mar 18; 46(3):716-23. PubMed ID: 11850253
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.